PIPELINE

Development Pipeline

Technology Therapeutic Area
  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3
POC Target*1
VCM*2 -
Emixustat HCl
Proliferative Diabetic
Retinopathy (PDR)
2017
Stargardt Disease
2018
AMD*3
2019
Lanosterol Cataract,
Presbyopia
2018
Optogenetics
(Gene Therapy)
Retinitis Pigmentosa
2019
ACU-6151 (Biomimetic
Technology)
Diabetic Macular Edema
(DME), Wet AMD, GA*4
2020
PBOS (Patient Based
Ophthalmology Suite)
DME, Wet AMD, Neovascular
Retinal Diseases
2019

Technology

VCM*2 - Emixustat HCl

Therapeutic Area

POC Target*1

Proliferative Diabetic
Retinopathy (PDR)

2017

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3

Therapeutic Area

POC Target*1

Stargardt Disease

2018

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3

Therapeutic Area

POC Target*1

AMD*3

2019

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3

Technology

Lanosterol

Therapeutic Area

POC Target*1

Cataract, Presbyopia

2018

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3

Technology

Optogenetics (Gene Therapy)

Therapeutic Area

POC Target*1

Retinitis Pigmentosa

2019

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3

Technology

ACU-6151 (Biomimetic Technology)

Therapeutic Area

POC Target*1

Diabetic Macular Edema (DME),
Wet AMD, GA*4

2020

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3

Technology

PBOS (Patient Based Ophthalmology Suite)

Therapeutic Area

POC Target*1

DME, Wet AMD,
Neovascular Retinal Diseases

2020

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3

  • *1 POC: Proof of Concept; the years listed are targets. For Stargardt Disease: Initial pharmacodynamic readout only.
  • *2 VCM: Visual Cycle Modulator
  • *3 AMD: Age-related Macular Degeneration
  • *4 GA: Geographic Atrophy

Therapeutics Development and Disease Indications